Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Pediacel™
DT5aP-IPV-Hib 5-component Pertussis vaccine · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Participants will receive PEDIACEL vaccine |
| Group 2 | ACTIVE_COMPARATOR | Participants will receive Infanrix-IPV+Hib vaccines |
| Name | Type | Description |
|---|---|---|
| DT5aP-IPV-Hib 5-component Pertussis vaccine | BIOLOGICAL | 0.5 mL, IM |
| Infanrix® -IPV+Hib | BIOLOGICAL | 0.5 mL, IM |
Inclusion Criteria: * Infants aged 80 to 120 days inclusive on the day of inclusion. * Born at full term of pregnancy (\> 37 weeks) * Informed consent form signed by the parent(s) or other legal representative according to local regulations * Parent(s) or legal representative able to attend all sch...
DT5aP-IPV-Hib is a combination vaccine developed by Sanofi that is designed to protect against pertussis along with diphtheria, tetanus, poliomyelitis, and Haemophilus influenzae type b. It is a five-component acellular pertussis vaccine intended for use in infants.
It is used for immunization against pertussis, diphtheria, tetanus, poliomyelitis, and Haemophilus influenzae type b disease. The Phase 3 trial studied it in infants from 80 days of age, given as a three-dose schedule.
Sanofi develops DT5aP-IPV-Hib, the five-component pertussis combination vaccine. Sanofi trades on the New York Stock Exchange under the ticker SNY.
DT5aP-IPV-Hib is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active.
The vaccine has been studied in the completed Phase 3 trial NCT00287092, which compared Pediacel and Infanrix IPV+Hib given in a three-dose schedule in infants. The randomized, double-blind, active-controlled trial enrolled 807 healthy infants in Finland and Sweden.